Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Drug Development Tool Qualification: US FDA Offers Three-Step Review Process

Executive Summary

FDA's proposed review timeline to qualify biomarkers, clinical outcome assessments, and animal models can actually be pretty quick – assuming submissions clear the initial "reviewability" hurdle. 

You may also be interested in...



US FDA Expands Drug Development Tool Qualification Program With ISTAND Pilot

ClinROs, artificial intelligence-based algorithms will be included in approval pathway. FDA is taking a crash course on new techniques for trial assessment thanks to COVID.

Evolution In Clinical Outcome Assessments Reflected In US FDA’s Revised Gastroparesis Guidance

Agency recommends an anchor-based approach to statistical analyses of drug effects on core signs and symptoms.

'Huge Need' For Neurotoxicity Biomarkers In Drug Development, FDA's Woodcock Says

"Perfect storm" makes it difficult to develop safety biomarkers, Woodcock tells US FDA workshop, citing lack of body charged with developing them and greater evidence required for their qualification.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS124429

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel